House Democrats are quickly intensifying oversight of the pharmaceutical industry, opening what may be one of the most significant investigations into prescription drug pricing in decades.

House Oversight Committee Chairman Elijah Cummings of Maryland sent letters to 12 drugmakers requesting detailed information and documentation on “price increases, investments in research and development, and corporate strategies to preserve market share and pricing power,” according to a statement.